Your browser doesn't support javascript.
loading
Prime-Boost Vaccine Regimen for SjTPI and SjC23 Schistosome Vaccines, Increases Efficacy in Water Buffalo in a Field Trial in China.
Da'Dara, Akram A; Li, Changlin; Yu, Xinling; Zheng, Mao; Zhou, Jie; Shollenberger, Lisa M; Li, Yue-Sheng; Harn, Donald A.
Afiliação
  • Da'Dara AA; Department of Infectious Diseases and Global Health, Tufts Cummings School of Veterinary Medicine, Tufts University, Grafton, MA, United States.
  • Li C; Department of Infectious Diseases and Center for Tropical and Emerging Global Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.
  • Yu X; Hunan Institute of Parasitic Diseases, World Health Organisation Collaborating Centre for Research and Control of Schistosomiasis in Lake Region, Yueyang, China.
  • Zheng M; Hunan Institute of Parasitic Diseases, World Health Organisation Collaborating Centre for Research and Control of Schistosomiasis in Lake Region, Yueyang, China.
  • Zhou J; Hunan Institute of Parasitic Diseases, World Health Organisation Collaborating Centre for Research and Control of Schistosomiasis in Lake Region, Yueyang, China.
  • Shollenberger LM; Department of Biological Sciences, Old Dominion University, Norfolk, VA, United States.
  • Li YS; Hunan Institute of Parasitic Diseases, World Health Organisation Collaborating Centre for Research and Control of Schistosomiasis in Lake Region, Yueyang, China.
  • Harn DA; Molecular Parasitology Laboratory, Infectious Diseases Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Front Immunol ; 10: 284, 2019.
Article em En | MEDLINE | ID: mdl-30842779
Schistosomiasis remains a serious zoonotic disease in China and the Philippines. Water buffalo and cattle account for the majority of transmission. Vaccination of water buffalo is considered a key strategy to reduce disease prevalence. Previously, we showed that vaccination of water buffalo with SjC23 or SjCTPI plasmid DNA vaccines, induced 50% efficacy to challenge infection. Here, we evaluated several parameters to determine if we can develop a two dose vaccine that maintains the efficacy of the three dose vaccine. We performed four trials evaluating: (1) lab produced vs. GLP grade vaccines, (2) varying the time between prime and boost, (3) the influence of an IL-12 adjuvant, and (4) a two dose heterologous (DNA-protein) prime-boost. We found the source of the DNA vaccines did not matter, nor did increasing the interval between prime and boost. Elimination of the IL-12 plasmid lowered homologous DNA-DNA vaccine efficacy. A major finding was that the heterologous prime boost improved vaccine efficacy, with the prime-boost regimen incorporating both antigens providing a 55% reduction in adult worms and 53% reduction in liver eggs. Vaccinated buffalo produced vaccine-specific antibody responses. These trials suggest that highly effective vaccination against schistosomes can be achieved using a two dose regimen. No adjuvants were used with the protein boost, and the potential that addition of adjuvant to the protein boost to further increase efficacy should be evaluated. These results suggest that use of these two schistosome vaccines can be part of an integrated control strategy to reduce transmission of schistosomiasis in Asia.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Schistosoma / Búfalos / Proteínas de Helminto / Vacinas de DNA Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Schistosoma / Búfalos / Proteínas de Helminto / Vacinas de DNA Idioma: En Ano de publicação: 2019 Tipo de documento: Article